AKT1-IN-13
AKT1-IN-13 is an orally active AKT1 inhibitor with an IC50 of 5.17 μM. AKT1-IN-13 also exhibits high inhibitory activity against PAK1, PKA, MAP2K1 (MEK1 / MAPKK1) and MAPK1 (ERK2). AKT1-IN-13 induces cell apoptosis, activates the pro-apoptotic protein BAX, inhibits the anti-apoptotic protein Bcl-2, and activates caspase 3 simultaneously. As a cytotoxic agent, AKT1-IN-13 exerts a killing effect on orthotopically transplanted liver cancer in an AKT1-dependent manner. AKT1-IN-13 can be used in studies related to hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Formula: C43H45BrN4O6
- Molecular Weight:793.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Akt1 5.17 μM (IC50) |
PAK1 |
MEK1 |
ERK2 |
Bax |
Bcl-2 |
Caspase 3 |
In Vitro
AKT1-IN-13 (Compound 17) (1.0 μM; 50 min) is a multi-target kinase inhibitor that potently inhibits AKT1 (with an inhibition rate of 95% at 1 μM), and exhibits an inhibition rate of > 80% against another 4 kinases (PAK1, PKA, MAP2K1, MAPK1) at 1 μM[1].
AKT1-IN-13 (72 h) potently inhibits the proliferation of human hepatocellular carcinoma HepG2 cells, with an IC50 of 2.09 μM and a selectivity index as high as 11.53[1].
AKT1-IN-13 (2-6 μM; 48 h) induces apoptosis in human hepatocellular carcinoma HepG2 cells in a concentration-dependent manner[1].
AKT1-IN-13 (2-6 μM; 48 h) inhibits the migration of human hepatocellular carcinoma HepG2 cells in a concentration-dependent manner[1].
AKT1-IN-13 (2-6 μM; 24 h) inhibits the invasion of human hepatocellular carcinoma HepG2 cells in a concentration-dependent manner[1].
AKT1-IN-13 (2-6 μM; 48 h) reduces the mitochondrial transmembrane potential of human hepatocellular carcinoma HepG2 cells in a concentration-dependent manner in vitro[1].
AKT1-IN-13 (2-6 μM; 48 h) induces G0/G1 cell cycle arrest in human hepatocellular carcinoma HepG2 cells in a concentration-dependent manner in vitro[1].
AKT1-IN-13 (2-6 μM; 48 h) inhibits AKT phosphorylation and activates the apoptotic pathway in a concentration-dependent manner in human hepatocellular carcinoma HepG2 cells in vitro, reduces p-AKT levels, and upregulates the expression of pro-apoptotic proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human liver cancer HepG2 cells
-
Concentration:2, 4 and 6 μM
-
Incubation Time:48 h
-
Result:Induced a concentration-dependent increase in apoptosis rates: early apoptosis rates rose from 2.42% (control) to 19.49% at 6 μM.
Caused morphological changes including loss of cell membrane smoothness and smaller nuclei.
-
Cell Line:human liver cancer HepG2 cells
-
Concentration:2, 4 and 6 μM
-
Incubation Time:48 h
-
Result:Inhibited HepG2 cell migration in a concentration-dependent manner, reducing the wound healing rate from 36.49% (control) to 3.43% at 6 μM.
-
Cell Line:human liver cancer HepG2 cells
-
Concentration:2, 4 and 6 μM
-
Incubation Time:24 h
-
Result:Inhibited HepG2 cell invasion in a concentration-dependent manner, reducing the percentage of invasive cells from 100% (control) to 19.85% at 6 μM.
-
Cell Line:human liver cancer HepG2 cells
-
Concentration:2, 4 and 6 μM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent G0/G1 phase arrest: the percentage of cells in G0/G1 phase increased from 65.30% (control) to 79.77% at 6 μM.
Decreased S phase percentage from 24.03% to 13.62% and G2/M phase percentage from 10.67% to 6.61%.
-
Cell Line:human liver cancer HepG2 cells
-
Concentration:2, 4 and 6 μM
-
Incubation Time:48 h
-
Result:Reduced p-AKT (Ser473) levels in a concentration-dependent manner (P < 0.01) while total AKT levels remained unchanged.
Decreased Bcl-2 expression, increased BAX expression, and elevated cleaved-caspase-3 and cleaved-PARP levels in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 3-4 weeks old, 16-18 g, orthotopic liver cancer transplantation model via Hepa1-6 cancer tissue implantation)[1]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:i.g.; daily; 14 days
-
Result:Reduced average tumor weight to 0.90 g (50 mg/kg group) and 0.86 g (100 mg/kg group) compared to 2.09 g in vehicle control group.
Reduced HCC cell infiltration, disordered arrangement, and multinuclear cell levels in treated groups relative to controls.
Reduced p-AKT levels significantly in both treatment groups compared to controls, with no significant change in total AKT protein levels.
Caused no significant changes in mouse body weight during the study period.
Chemical Information
-
Molecular Weight 793.74
-
Formula C43H45BrN4O6
-
SMILES
COC1=CC(NC2=CC=C(N=C2)Br)=C3C=C1OC4=CC=CC(C[C@H]5C6=C(CCN5C)C=C(C(OC7=C8C(CCN([C@H]8C3)C)=CC(OC)=C7OC)=C6)OC)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1].
Hou H, et al. Design, Synthesis, and Biological Evaluation of Novel Tetrandrine Derivatives Targeting AKT1 for Hepatocellular Carcinoma Therapy: Integration of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation. ACS Omega. 2026 May 20;11(21):30812-30833.
[Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)